ARGX vs GILD
Argenx SE and Gilead Sciences, Inc., side by side — 10 fiscal years reported in USD, drawn from SEC filings.
At a glance
Most recent reported year
| Metric | ARGX | GILD |
|---|---|---|
| Revenue | $4.2B | $29.4B |
| Net income | $1.3B | $8.5B |
| Gross margin | 89.1% | 78.8% |
| Net margin | 31.1% | 28.9% |
| Return on equity | — | 40.5% |
| Diluted EPS | $19.57 | $6.78 |
| Dividend / share | — | $3.16 |
| Payout ratio | — | 47.0% |
| Free cash flow | $679.0M | $9.5B |
| Equity | — | $22.7B |
| Net debt / equity | — | 0.77× |
| Current ratio | 5.23× | 1.55× |
| Revenue CAGR 5y | 151.5% | 3.6% |
| Profit CAGR 5y | — | 133.3% |
GILD bills 7.1× the revenue of ARGX, and ARGX keeps more of each dollar of revenue as profit (31.1% against 28.9%).
The stronger figure of the pair is set in bold. That is arithmetic, not a recommendation — this page does not pick a winner.
Advertisement
AdSense · Leaderboard 728×90 · responsive
Revenue by year
10 years side by side
| Fiscal year | ARGX | GILD |
|---|---|---|
| FY2025 | $4.2B | $29.4B |
| FY2024 | $2.2B | $28.8B |
| FY2023 | $1.2B | $27.1B |
| FY2022 | $400.7M | $27.3B |
| FY2021 | $497.3M | $27.3B |
| FY2020 | $41.2M | $24.7B |
| FY2019 | $78.5M | $22.4B |
| FY2018 | $21.5M | $22.1B |
| FY2017 | $36.4M | $26.1B |
| FY2016 | $14.7M | $30.4B |
Net income by year
Bottom line
| Fiscal year | ARGX | GILD |
|---|---|---|
| FY2025 | $1.3B | $8.5B |
| FY2024 | $833.0M | $480.0M |
| FY2023 | $-295.1M | $5.7B |
| FY2022 | $-709.6M | $4.6B |
| FY2021 | $-408.3M | $6.2B |
| FY2020 | $-608.5M | $123.0M |
| FY2019 | $-181.2M | $5.4B |
| FY2018 | $-66.6M | $5.5B |
| FY2017 | $-28.1M | $4.6B |
| FY2016 | $-21.4M | $13.5B |
Advertisement
AdSense · Rectangle 336×280
More in this industry